Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages.

Wajant H, Siegmund D.

Front Cell Dev Biol. 2019 May 29;7:91. doi: 10.3389/fcell.2019.00091. eCollection 2019. Review.

2.

Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target.

Medler J, Wajant H.

Expert Opin Ther Targets. 2019 Apr;23(4):295-307. doi: 10.1080/14728222.2019.1586886. Epub 2019 Mar 19.

PMID:
30856027
3.

TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.

Medler J, Nelke J, Weisenberger D, Steinfatt T, Rothaug M, Berr S, Hünig T, Beilhack A, Wajant H.

Cell Death Dis. 2019 Mar 4;10(3):224. doi: 10.1038/s41419-019-1456-x.

4.

Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling.

Füllsack S, Rosenthal A, Wajant H, Siegmund D.

Cell Death Dis. 2019 Feb 11;10(2):122. doi: 10.1038/s41419-019-1396-5.

5.

Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis.

Anany MA, Kreckel J, Füllsack S, Rosenthal A, Otto C, Siegmund D, Wajant H.

Cell Death Dis. 2018 Oct 22;9(11):1084. doi: 10.1038/s41419-018-1137-1.

6.

TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signaling.

Siegmund D, Ehrenschwender M, Wajant H.

Cell Death Dis. 2018 Sep 11;9(9):921. doi: 10.1038/s41419-018-0973-3.

7.

New Cytotoxic Cyclic Peptide from the Marine Sponge-Associated Nocardiopsis sp. UR67.

Ibrahim AH, Attia EZ, Hajjar D, Anany MA, Desoukey SY, Fouad MA, Kamel MS, Wajant H, Gulder TAM, Abdelmohsen UR.

Mar Drugs. 2018 Aug 21;16(9). pii: E290. doi: 10.3390/md16090290.

8.

Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation.

Cuchet-Lourenço D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, Ceron-Gutierrez L, Bacon CM, Hackett S, Alsaleem B, Maes M, Gaspar M, Alisaac A, Goss E, AlIdrissi E, Siegmund D, Wajant H, Kumararatne D, AlZahrani MS, Arkwright PD, Abinun M, Doffinger R, Nejentsev S.

Science. 2018 Aug 24;361(6404):810-813. doi: 10.1126/science.aar2641. Epub 2018 Jul 19.

9.
10.

Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.

Sirtl S, Knoll G, Trinh DT, Lang I, Siegmund D, Gross S, Schuler-Thurner B, Neubert P, Jantsch J, Wajant H, Ehrenschwender M.

Oncogene. 2018 Jul;37(30):4122-4136. doi: 10.1038/s41388-018-0265-5. Epub 2018 Apr 30.

11.

Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.

Ticha O, Moos L, Wajant H, Bekeredjian-Ding I.

Front Immunol. 2018 Jan 19;8:1951. doi: 10.3389/fimmu.2017.01951. eCollection 2017.

12.

[Biofabrication: new approaches for tissue regeneration].

Horch RE, Weigand A, Wajant H, Groll J, Boccaccini AR, Arkudas A.

Handchir Mikrochir Plast Chir. 2018 Apr;50(2):93-100. doi: 10.1055/s-0043-124674. Epub 2018 Jan 29. German.

PMID:
29378379
13.

Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice.

Lamontain V, Schmid T, Weber-Steffens D, Zeller D, Jenei-Lanzl Z, Wajant H, Straub RH, Männel DN.

Cell Mol Immunol. 2019 Jan;16(1):65-74. doi: 10.1038/cmi.2017.138. Epub 2018 Jan 29.

PMID:
29375132
14.

Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation.

Schmid T, Falter L, Weber S, Müller N, Molitor K, Zeller D, Weber-Steffens D, Hehlgans T, Wajant H, Mostböck S, Männel DN.

Front Immunol. 2017 Nov 7;8:1471. doi: 10.3389/fimmu.2017.01471. eCollection 2017.

15.

The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent.

Lagler C, El-Mesery M, Kübler AC, Müller-Richter UDA, Stühmer T, Nickel J, Müller TD, Wajant H, Seher A.

PLoS One. 2017 Oct 13;12(10):e0185720. doi: 10.1371/journal.pone.0185720. eCollection 2017.

16.

TRAIL- and TNF-induced signaling complexes-so similar yet so different.

Wajant H.

EMBO J. 2017 May 2;36(9):1117-1119. doi: 10.15252/embj.201796997. Epub 2017 Apr 11. No abstract available.

17.

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

Kums J, Nelke J, Rüth B, Schäfer V, Siegmund D, Wajant H.

MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.

18.

Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.

Lang I, Kums J, Wajant H.

Methods Mol Biol. 2017;1557:63-77. doi: 10.1007/978-1-4939-6780-3_7.

PMID:
28078583
19.

Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis.

Siegmund D, Kums J, Ehrenschwender M, Wajant H.

Cell Death Dis. 2016 Sep 22;7(9):e2375. doi: 10.1038/cddis.2016.285.

20.

Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination.

Dagvadorj N, Deuretzbacher A, Weisenberger D, Baumeister E, Trebing J, Lang I, Köchel C, Kapp M, Kapp K, Beilhack A, Hünig T, Einsele H, Wajant H, Grigoleit GU.

Cancer Immunol Immunother. 2017 Mar;66(3):319-332. doi: 10.1007/s00262-016-1938-y. Epub 2016 Nov 28.

PMID:
27896368
21.

Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.

Grabinger T, Bode KJ, Demgenski J, Seitz C, Delgado ME, Kostadinova F, Reinhold C, Etemadi N, Wilhelm S, Schweinlin M, Hänggi K, Knop J, Hauck C, Walles H, Silke J, Wajant H, Nachbur U, W Wei-Lynn W, Brunner T.

Gastroenterology. 2017 Mar;152(4):867-879. doi: 10.1053/j.gastro.2016.11.019. Epub 2016 Nov 24.

22.

Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.

Siegmund D, Lang I, Wajant H.

FEBS J. 2017 Apr;284(8):1131-1159. doi: 10.1111/febs.13968. Epub 2016 Dec 14. Review.

23.

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.

24.

Therapeutic targeting of CD70 and CD27.

Wajant H.

Expert Opin Ther Targets. 2016 Aug;20(8):959-73. doi: 10.1517/14728222.2016.1158812. Epub 2016 Mar 15. Review.

PMID:
26914723
25.

Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Lang I, Füllsack S, Wyzgol A, Fick A, Trebing J, Arana JA, Schäfer V, Weisenberger D, Wajant H.

J Biol Chem. 2016 Mar 4;291(10):5022-37. doi: 10.1074/jbc.M115.683946. Epub 2015 Dec 31.

26.

Soluble TL1A is sufficient for activation of death receptor 3.

Bittner S, Knoll G, Füllsack S, Kurz M, Wajant H, Ehrenschwender M.

FEBS J. 2016 Jan;283(2):323-36. doi: 10.1111/febs.13576. Epub 2015 Nov 24.

27.

Principles of antibody-mediated TNF receptor activation.

Wajant H.

Cell Death Differ. 2015 Nov;22(11):1727-41. doi: 10.1038/cdd.2015.109. Epub 2015 Aug 21. Review.

28.

Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H.

Blood. 2015 Jul 23;126(4):437-44. doi: 10.1182/blood-2015-01-620583. Epub 2015 May 26.

29.

XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.

Ehrenschwender M, Bittner S, Seibold K, Wajant H.

Cell Death Dis. 2014 Dec 11;5:e1570. doi: 10.1038/cddis.2014.534.

30.

MLN4924 sensitizes monocytes and maturing dendritic cells for TNF-dependent and -independent necroptosis.

El-Mesery M, Seher A, Stühmer T, Siegmund D, Wajant H.

Br J Pharmacol. 2015 Mar;172(5):1222-36. doi: 10.1111/bph.12998. Epub 2015 Jan 13.

31.

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis.

Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M, Wajant H, Giner T.

Cell Death Dis. 2014 Oct 9;5:e1444. doi: 10.1038/cddis.2014.404. Erratum in: Cell Death Dis. 2014;5:e1556.

32.

Principles and mechanisms of CD95 activation.

Wajant H.

Biol Chem. 2014 Dec;395(12):1401-16. doi: 10.1515/hsz-2014-0212. Review.

PMID:
25153377
33.

Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling.

Joedicke JJ, Myers L, Carmody AB, Messer RJ, Wajant H, Lang KS, Lang PA, Mak TW, Hasenkrug KJ, Dittmer U.

J Immunol. 2014 Sep 15;193(6):2952-60. doi: 10.4049/jimmunol.1400649. Epub 2014 Aug 6.

34.

Analyzing the signaling capabilities of soluble and membrane TWEAK.

Trebing J, Arana JA, Salzmann S, Wajant H.

Methods Mol Biol. 2014;1155:31-45. doi: 10.1007/978-1-4939-0669-7_4.

PMID:
24788171
35.

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Brunekreeft KL, Strohm C, Gooden MJ, Rybczynska AA, Nijman HW, Grigoleit GU, Helfrich W, Bremer E, Siegmund D, Wajant H, de Bruyn M.

Mol Cancer. 2014 Apr 17;13:85. doi: 10.1186/1476-4598-13-85.

36.

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.

37.

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.

Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ.

MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6.

38.

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H.

Cell Death Dis. 2014 Jan 30;5:e1035. doi: 10.1038/cddis.2013.555.

39.

Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor.

Fischer R, Wajant H, Kontermann R, Pfizenmaier K, Maier O.

Glia. 2014 Feb;62(2):272-83. doi: 10.1002/glia.22605. Epub 2013 Dec 6.

PMID:
24310780
40.

Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation.

Pachel C, Mathes D, Bayer B, Dienesch C, Wangorsch G, Heitzmann W, Lang I, Ardehali H, Ertl G, Dandekar T, Wajant H, Frantz S.

PLoS One. 2013 Nov 11;8(11):e78938. doi: 10.1371/journal.pone.0078938. eCollection 2013.

41.

CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.

El-Mesery M, Trebing J, Schäfer V, Weisenberger D, Siegmund D, Wajant H.

Cell Death Dis. 2013 Nov 14;4:e916. doi: 10.1038/cddis.2013.402.

42.

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.

Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, Riedel SS, Siegmund D, Beilhack A, Otto C, Wajant H.

MAbs. 2014 Jan-Feb;6(1):297-308.

43.

Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.

Haselmann V, Kurz A, Bertsch U, Hübner S, Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Röder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Böger C, Knippschild U, Röcken C, Adam D, Walczak H, Schütze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A.

Gastroenterology. 2014 Jan;146(1):278-90. doi: 10.1053/j.gastro.2013.10.009. Epub 2013 Oct 9.

PMID:
24120475
44.

Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1.

Chopra M, Lang I, Salzmann S, Pachel C, Kraus S, Bäuerlein CA, Brede C, Garrote AL, Mattenheimer K, Ritz M, Schwinn S, Graf C, Schäfer V, Frantz S, Einsele H, Wajant H, Beilhack A.

PLoS One. 2013 Sep 30;8(9):e75737. doi: 10.1371/journal.pone.0075737. eCollection 2013.

45.

The TWEAK-Fn14 system as a potential drug target.

Wajant H.

Br J Pharmacol. 2013 Oct;170(4):748-64. doi: 10.1111/bph.12337. Review.

46.

TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.

Salzmann S, Lang I, Rosenthal A, Schäfer V, Weisenberger D, Carmona Arana JA, Trebing J, Siegmund D, Neumann M, Wajant H.

J Immunol. 2013 Sep 1;191(5):2308-18. doi: 10.4049/jimmunol.1202899. Epub 2013 Aug 5.

47.

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H.

J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26.

48.

The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.

Rauert-Wunderlich H, Siegmund D, Maier E, Giner T, Bargou RC, Wajant H, Stühmer T.

PLoS One. 2013;8(3):e59292. doi: 10.1371/journal.pone.0059292. Epub 2013 Mar 20.

49.

Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.

Chopra M, Riedel SS, Biehl M, Krieger S, von Krosigk V, Bäuerlein CA, Brede C, Jordan Garrote AL, Kraus S, Schäfer V, Ritz M, Mattenheimer K, Degla A, Mottok A, Einsele H, Wajant H, Beilhack A.

Carcinogenesis. 2013 Jun;34(6):1296-303. doi: 10.1093/carcin/bgt038. Epub 2013 Feb 5.

PMID:
23385062
50.

Activation of the aryl hydrocarbon receptor sensitises human keratinocytes for CD95L- and TRAIL-induced apoptosis.

Stolpmann K, Brinkmann J, Salzmann S, Genkinger D, Fritsche E, Hutzler C, Wajant H, Luch A, Henkler F.

Cell Death Dis. 2012 Sep 6;3:e388. doi: 10.1038/cddis.2012.127.

Supplemental Content

Loading ...
Support Center